HIF1A and neoplasm: ATR kinase is a major DNA damage repair protein whose inhibitors have emerged as a promising strategy for cancer treatment and are currently being evaluated in pateints with various solid cancers.[21, 57] However, recent evidence suggests the possibility of non‐DDR functions of ATR in tumor hypoxia, which are critical for the survival of hypoxic cancer cells.[32, 33] Consistent with these reports, we demonstrated that hypoxia sensitised TNBC cells to AZD6738, an ATR inhibitor (Figure 1), through the inhibition of HIF‐1A mediated hypoxia reponses (Figure 2).